Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults
Diabetes, Obesity and Metabolism · 2023-11 · 25 (11) · 3390-3399
DOI: 10.1111/dom.15238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.08.2023. Verfasst von Kang Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Overweight, Obesity. Die Arbeit wurde bisher 395-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
To evaluate the prevalence of overweight/obesity and associated complications from a large, cross‐sectional, nationwide database in China. Materials and Methods Data were obtained from 519 Meinian health check‐up centres across 243 cities. Eligible participants were aged ≥18 years, with a routine check‐up in 2019 (N = 21 771 683) and complete height, weight, sex and region data. The unadjusted prevalence rates of overweight/obesity were calculated by age, sex and region. In addition, the nationwide prevalence rates of overweight and obesity were standardized according to the 2010 China census by age group and sex. The prevalence of obesity‐related complications by body mass index (BMI) groups was calculated using logistic regression.
Results
There were 15 770 094 eligible participants (median age 40 years; mean BMI 24.1 kg/m 2 ; 52.8% male). By Chinese BMI classification, 34.8% were overweight and 14.1% were obese. Overweight and obesity were more prevalent in male than female participants (standardized: overweight 40.2% vs. 27.4%; obesity 17.6% vs. 9.6%, respectively). The prevalence of assessed complications was higher in participants with overweight/obesity versus those with normal BMI ( P < 0.001 for trends). The most prevalent complications in participants with overweight/obesity were fatty liver disease, prediabetes, dyslipidaemia and hypertension. The number of complications increased with higher BMI.
Conclusions
Overweight/obesity and related complications are highly prevalent in this population. These data may better inform management and prevention public health strategies in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, First Medical Center of Chinese PLA General Hospital, Beijing, China.
- Biostatistics and Data Science, Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China.
- Medical Affairs, Novo Nordisk (China) Pharmaceuticals Co., Ltd, Beijing, China.
- Meinian Institute of Health, Beijing, China.
Zitieren
APA
Chen, K., Shen, Z., Gu, W., Lyu, Z., Qi, X., Mu, Y., Ning, Y., & Meinian Investigator Group (2023). Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults. Diabetes, Obesity and Metabolism, 25(11), 3390-3399. https://doi.org/10.1111/dom.15238
Vancouver
Chen K, Shen Z, Gu W, Lyu Z, Qi X, Mu Y, et al. Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults. Diabetes, Obesity and Metabolism. 2023;25(11):3390-3399. doi:10.1111/dom.15238
BibTeX
@article{Chen2023,
author = {Chen, Kang and Shen, Zewei and Gu, Weijun and Lyu, Zhaohui and Qi, Xuan and Mu, Yiming and Ning, Yi and Meinian Investigator Group, Meinian Investigator Group},
title = {Prevalence of obesity and associated complications in China: A cross‐sectional, real‐world study in 15.8 million adults},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
volume = {25},
number = {11},
pages = {3390--3399},
doi = {10.1111/dom.15238}
}
EUVIMED